Substituted pyrrolidines as mGluR5 antagonists
US10328054B2 · kind B2 · utility
0Cited by
0References
24Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 21, 2016 |
| Grant date | Jun 25, 2019 |
| Priority date | — |
| Expiry date | Oct 21, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D471/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are compounds of the formula (I), as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment or prevention of mGluR5 mediated disorders, such as acute and/or chronic neurological disorders, cognitive disorders and memory deficits, as well as acute and chronic pain.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.